These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 35602377)

  • 21. Treatment of psychiatric disturbances in hypokinetic movement disorders.
    Berardelli I; Belvisi D; Pasquini M; Fabbrini A; Petrini F; Fabbrini G
    Expert Rev Neurother; 2019 Oct; 19(10):965-981. PubMed ID: 31241368
    [No Abstract]   [Full Text] [Related]  

  • 22. New Pharmacological Approaches to Treating Non-Motor Symptoms of Parkinson's Disease.
    Kelberman MA; Vazey EM
    Curr Pharmacol Rep; 2016 Dec; 2(6):253-261. PubMed ID: 28534003
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment Possibilities for Psychosis in Parkinson's Disease with An Emphasis on the Newly Approved Drug: Pimavanserin.
    Majlath Z; Obal I; Vecsei L
    CNS Neurol Disord Drug Targets; 2017; 16(3):234-243. PubMed ID: 27719624
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neuropsychiatric Symptoms in Parkinson's Disease.
    Aarsland D; Kramberger MG
    J Parkinsons Dis; 2015; 5(3):659-67. PubMed ID: 26406147
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Advances in Management of Psychosis in Neurodegenerative Diseases.
    Rothenberg KG; Rajaram R
    Curr Treat Options Neurol; 2019 Jan; 21(1):3. PubMed ID: 30673880
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease.
    Rolinski M; Fox C; Maidment I; McShane R
    Cochrane Database Syst Rev; 2012 Mar; 2012(3):CD006504. PubMed ID: 22419314
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Course of psychiatric symptoms and global cognition in early Parkinson disease.
    de la Riva P; Smith K; Xie SX; Weintraub D
    Neurology; 2014 Sep; 83(12):1096-103. PubMed ID: 25128183
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Parkinson's disease as a neuropsychiatric disorder].
    Sommer IE; van Laar T
    Ned Tijdschr Geneeskd; 2019 Aug; 163():. PubMed ID: 31386313
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multifactorial sleep disturbance in Parkinson's disease.
    Albers JA; Chand P; Anch AM
    Sleep Med; 2017 Jul; 35():41-48. PubMed ID: 28619181
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Increased risk of impulse control symptoms in Parkinson's disease with REM sleep behaviour disorder.
    Fantini ML; Macedo L; Zibetti M; Sarchioto M; Vidal T; Pereira B; Marques A; Debilly B; Derost P; Ulla M; Vitello N; Cicolin A; Lopiano L; Durif F
    J Neurol Neurosurg Psychiatry; 2015 Feb; 86(2):174-9. PubMed ID: 25006210
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pimavanserin Treatment for Parkinson's Disease Psychosis in Clinical Practice.
    Dashtipour K; Gupta F; Hauser RA; Karunapuzha CA; Morgan JC
    Parkinsons Dis; 2021; 2021():2603641. PubMed ID: 33489083
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of psychiatric and other nonmotor symptoms on disability in Parkinson's disease.
    Weintraub D; Moberg PJ; Duda JE; Katz IR; Stern MB
    J Am Geriatr Soc; 2004 May; 52(5):784-8. PubMed ID: 15086662
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Psychiatric care in Parkinson's disease.
    Quelhas R
    J Psychiatr Pract; 2013 Mar; 19(2):118-41. PubMed ID: 23507813
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mild cognitive impairment, psychiatric symptoms, and executive functioning in patients with Parkinson's disease.
    Petkus AJ; Filoteo JV; Schiehser DM; Gomez ME; Hui JS; Jarrahi B; McEwen S; Jakowec MW; Petzinger GM
    Int J Geriatr Psychiatry; 2020 Apr; 35(4):396-404. PubMed ID: 31894601
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impulse control disorder in patients with Parkinson's disease under dopamine agonist therapy: a multicentre study.
    Garcia-Ruiz PJ; Martinez Castrillo JC; Alonso-Canovas A; Herranz Barcenas A; Vela L; Sanchez Alonso P; Mata M; Olmedilla Gonzalez N; Mahillo Fernandez I
    J Neurol Neurosurg Psychiatry; 2014 Aug; 85(8):840-4. PubMed ID: 24434037
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impulse control and related disorders in Parkinson's disease.
    Weintraub D; Nirenberg MJ
    Neurodegener Dis; 2013; 11(2):63-71. PubMed ID: 23038208
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An Update on Medical and Surgical Treatments of Parkinson's Disease.
    Nemade D; Subramanian T; Shivkumar V
    Aging Dis; 2021 Jul; 12(4):1021-1035. PubMed ID: 34221546
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New insight into the therapeutic role of the serotonergic system in Parkinson's disease.
    Ohno Y; Shimizu S; Tokudome K; Kunisawa N; Sasa M
    Prog Neurobiol; 2015 Nov; 134():104-21. PubMed ID: 26455457
    [TBL] [Abstract][Full Text] [Related]  

  • 39. What can rodent models tell us about apathy and associated neuropsychiatric symptoms in Parkinson's disease?
    Magnard R; Vachez Y; Carcenac C; Krack P; David O; Savasta M; Boulet S; Carnicella S
    Transl Psychiatry; 2016 Mar; 6(3):e753. PubMed ID: 26954980
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Psychosis in Parkinson's Disease: Epidemiology, Pathophysiology, and Management.
    Chang A; Fox SH
    Drugs; 2016 Jul; 76(11):1093-118. PubMed ID: 27312429
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.